Skip to main content
Evidence Snapshot

Oxysterols receptor LXR-alpha

CHEMBL2808 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2808
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Oxysterols receptor LXR-alpha as ChEMBL target CHEMBL2808, mapped to UniProt Q13133. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Oxysterols receptor LXR-alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2808
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13133
Oxysterols receptor LXR-alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Oxysterols receptor LXR-alpha matters

As of 2026-09-13

Oxysterols receptor LXR-alpha is reviewed as Oxysterols receptor LXR-alpha (UniProt Q13133); Oxysterols receptor LXR-alpha shows clinical signal disease relevance led by Hypercholesterolemia.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 1773 compounds, and 457 assays, with lead potency reaching pChEMBL 9.1.

Disease context
Hypercholesterolemia

Oxysterols receptor LXR-alpha shows clinical signal disease relevance led by Hypercholesterolemia. 2 linked drugs keep the rationale reviewable. Linked drugs include BMS-852927, HYODEOXYCHOLIC_ACID.

Start review with Hypercholesterolemia because it currently carries clinical signal support. Linked drugs include BMS-852927, HYODEOXYCHOLIC_ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 1773 compounds, and 457 assays for this target. The dominant activity type is EC50. CHEMBL595012 is the current potency anchor at pChEMBL 9.1.

Use CHEMBL595012 as the tractability anchor when discussing potency (pChEMBL 9.1).

Activity source · ChEMBL 36 via Core Engine
2 approved pChEMBL 9.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Oxysterols receptor LXR-alpha matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13133, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Hypercholesterolemia is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1773
Total Compounds
457
Total Assays
2
Approved Drugs
IC50: 670.0, KI: 445.0, EC50: 1069.0, KD: 13.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL595012
 9.1 IC50 —
No preferred name
CHEMBL611735
 9.1 IC50 —
No preferred name
CHEMBL592506
 9.0 IC50 —
No preferred name
CHEMBL555373
 9.0 EC50 —
No preferred name
CHEMBL365544
 9.0 EC50 —

Approved Drugs

Structure Compound First Approval
BEXAROTENE
CHEMBL1023
 1999
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2808